Marc Gleeson

Azura Ophthalmics Announces Formation of Scientific Advisory Board (SAB)

Eye-drug developer Azura Ophthalmics, working from Melbourne and Tel Aviv, has assembled a seven-member scientific advisory board of ophthalmology specialists to guide clinical development of its lead candidate AZR-MD-001.

Azura Ophthalmics Secures Grant to Evaluate AZR-MD-001 for Improved Vision Quality Related to Contact Lens Discomfort

Azura Ophthalmics won a CUREator grant to fund a two-stage study of its AZR-MD-001 candidate for contact lens discomfort, extending pilot research conducted with UNSW; the incubator program is run by Brandon BioCatalyst.

Also Brandon BioCatalyst portfolio